the JaK2 mutation in myeloproliferative neoplasms: a predictive factor of thrombosis
##plugins.themes.academic_pro.article.main##
Abstract
SUMMARY
Background: BCR-ABL negative myeloproliferative neoplasms (MPN) include polycythemia Vera (PV), essential thrombocythemia (ET) and primitive myelofibrosis (PMF). the JAK2 V617F mutation has been introduced since 2008 as a major diagnostic criterion on the one hand and on the other hand, it would be linked to increased risk of thrombotic complications.
Aim: This study aimed to evaluate the association of JAK2 mutation and thrombotic events in MPN.
Methods: A retrospective study concerning 45 BCR-ABL negative MPN patients (mean age=53 old years, sex ratio=0.8) was conducted.
Results: They were classified as PV (22 patients), ET (17 patients), PMF (3 patients) and atypical MPN (3 patients). The JAK2 mutation was found in 64.4% of patients: 72.7% of PV patients, 47% of ET patients and 66.7% of PMF patients. Thrombotic events were recorded in 11 patients (24.4%). Cerebral arteries and portal vein were the most frequent localizations. The JAK2 mutation was an independent risk factor of thrombotic events.
Conclusion: Consequently, it seems that screening for JAK2 mutation in BCR-ABL negative MPN could play a role in identifying patients at high risk of vascular complications.
Keywords:
Myeloproliferative neoplasms - JAK2 mutation - thrombosis##plugins.themes.academic_pro.article.details##
References
- Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35:1704-7
- Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of JAK2 mutation with risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systematic review. Thrombosis Research 2009; 124; 409-17
- Barbui T, Carrobio A, Rambaldi A et finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114:759-63
- Finazzi G, Rambaldi A, guerini V, Carobbo A et Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F status Haematologica 2007; 92:135-6
- Barbui T, Barosi G, Birgegard G, Cervantes F, finazzi G, Grieshammer M et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommandations from europeen Leukemia Net. J Clin Oncol 2011; 29:761-70
- Vardiman JW, thiele J, Arber DA, Bruning RD, Borowitz MJ, Powit A et al. the 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukemia rationale and important changes. Blood 2009; 114: 937-51
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the thyrosin kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61
- Carrobia A, Finazzia G, Antoniolib E, Guglielmellib P, Vannucchib AM, Dellacas CM. JAK2 V617F allele burden and thrombosis: a direct comparision in essential thrombocythemia and polycythemia vera. Experimental Hematology 2009; 37: 1016-21
- Siemiatkowska A, Bieniaszewskab M, Hellmannb A, Limona J. JAK2 and MPL gene mutations in V617F negative myeloproliferative neoplasms. Leukemia Research 2010; 34: 387-9
- Kralovics R, Passamonti F, buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90
- Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T et al. JAK2 V617F mutation analysis of granulocytosis and platelets from patients with chronic myeloproliferative disorders: advantages of studying platelets. Br J Haematol 2007; 139:64-9
- Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutaded status is associated with inferior overall and leukemia free survival Leukemia 2008; 22:756-61
- Elliot M and Tefferi A. Thrombosis and haemorrage in polycythemia vera and essential thrombocythemia Br J haematol 2005; 128:275-90
- Falanga A et Marchetti M. Thrombotic disease in myeloproliferative neoplasms Hematology 2012; 571-81
- Landolfi R, Gennaro LD et Falanga A. Thrombosis in myeloproliferative disorders: pathogenic facts and speculation. Leukemia 2008; 22:2020-8
- Prea G, Remacha A, Besses C, Jimenez M, florensa L, cervantes F et al. polycythemia vera a serious disease in young adults? Hematologica 2001; 86:543-4
- Smalberg Jh, Arends LR, Valla DC, Kiladjian JJ, Janseen HL, Leebeek FW. Myeloproliferative neoplasms in Budd Chiari sundrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120:4921-8
- Barbui T, Finazzi G, Carobbio a, thiele J, Passamonti F, Rumi E et al. Development and validation of an international Prognostic Score of thrombosis in World Health Organisation- essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128-33.
- Barbui T, Finazzi G and Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013: 122; 2176-84
- Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013; 11:1215-27